Home | Welcome to Contract Pharma   
Last Updated Thursday, April 24 2014
Print

Tekmira Receives Alnylam Milestone



By Kristin Brooks



Published December 17, 2013
Related Searches: Phase III Validation
Tekmira Pharmaceuticals has received a $5 million milestone from Alnylam Pharmaceuticals for the initiation of a Phase III Patisiran trial. Patisiran, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR), is enabled by Tekmira's lipid nanoparticle (LNP) technology. Tekmira is also entitled to ongoing royalties related to product commercialization.
 
"We are proud that our proprietary LNP delivery technology is enabling the most advanced applications of RNAi in the clinic. As this ground-breaking class of therapeutics matures and reaches important milestones, such as patisiran entering a Phase III clinical trial, we gain further validation of the efficacy and safety of Tekmira's LNP technology platform," said Dr. Mark J. Murray, Tekmira's president and chief executive officer.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On